TLR4 and influenza: Overall, TLR4 agonist-based adjuvants (MPL and GLA formulations) robustly enhance vaccine efficacy by promoting broad, durable, and cross-protective immune responses, making them powerful tools for the development of the next generation of universal influenza vaccine.